Loading…
← CockpitCompetitor Analysis › 310210.KS Voronoi, Inc.Open in the cockpit ↗

Voronoi, Inc.310210.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biotech developing small-molecule kinase-inhibitor cancer drugs, licensing candidates to global and regional pharma partners.

Momentum laggard 8
Mkt cap
$1.43B
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$5.92M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-149.7 pp
WACC 7.9%
Hurdle
n/a
no reverse DCF
Close · KRW₩101,800
1D+0.7%
1W-12.2%
1M-22.8%
3M-43.4%
6M-61.9%
YTD-53.2%
1Y-49.7%
ATR %10.3%
52w lowhigh72.9% off high

What Voronoi does

Korean biotech developing small-molecule kinase-inhibitor cancer drugs, licensing candidates to global and regional pharma partners.

Its income comes from licensing fees and milestone payments received when partners pay for rights and development progress, so results depend on the timing of deal payments rather than steady sales.

Products and services

  • Kinase-inhibitor oncology pipeline
  • Licensed drug candidates

Customers

  • Global/regional pharma licensing partners

Where it sits in the supply chain

  • Biotechnology
  • Small-molecule kinase-inhibitor…
  • Global pharma licensing

What could go right

  • New licensing deals
  • Clinical progress on lead candidates

What could go wrong

  • Clinical-trial failure risk
  • Early-stage pipeline concentration

Moat: narrow (IP / patents). AI-assisted drug-design platform generating novel kinase inhibitors licensed to partners.

Headquarters: Seoul, South Korea · Founded: 2015 · Employees: 149

Named competitors

Voronoi at a glance

Size Voronoi (310210.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 185th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩101,800 on 18 Nov 2026.

Performance Over six months the shares fell 61.9%, against -9.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue fell 99.7% over the last twelve months (peer median +14.4%); the operating margin is -438,151.7% (peer median 10.9%).

Valuation It trades at 85,633.6× enterprise value to sales against a peer median of 3.9× (most expensive of 19).

Capital Return on invested capital runs 149.7 points below its cost of capital (7.9% WACC).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 92310210.KS 38
Six months, rebased to 100: Voronoi against the median of its 20 peers (local-currency closes).

Voronoi financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩22.1M₩7.51B₩0₩0₩9.77B
Revenue growth———-100%—
Gross profitn/an/a-₩1.97B-₩2.71Bn/a
EBITDA-₩94.2B-₩52.6B-₩34.4B-₩28.6B-₩15.5B
Net income-₩85.8B-₩42.7B-₩32.6B-₩36.8B-₩19.9B
Free cash flow-₩118B-₩73.7B-₩30.2B-₩29.9B-₩16.9B
Capital expenditure₩4.83B₩1.68B₩1.23B₩1.08B₩552M
Total debt₩17.8B₩39.8B₩990M₩12.3B₩25.7B

Quarterly statements and history in the cockpit →

Voronoi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-20%0%+20%MARKSANS1404104516DMRAPAHC002626002020CORONA141080226950298380NANO603235600572068760688293MNKD310210.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Voronoi is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%0×25,000×50,000×75,000×MARKSANS140410002626141080298380NANO688293310210.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Voronoi is the large dot.

Voronoi competitors and peer comparison

Head to head with its named competitors (310210.KS vs 039200.KS vs 128940.KS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Voronoi 310210.KS$1.43B-62%-100%-438,152%85,633.6×n/a
Oscotec 039200.KS$923M-32%+510%59%7.5×-10.2%
HanmiPharm 128940.KS$3.95B-2%+14%16%3.3×4.7%

How Voronoi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Voronoi against its 20 peers (data as of 18 Nov 2026)
Measure310210.KSPeer medianRank in peer set
1-month return-22.8%-2.8%2nd lowest of 20
6-month return-61.9%-9.1%3rd lowest of 20
Distance from 52-week high-72.9%-40.0%3rd lowest of 20
Revenue growth (TTM)-99.7%+14.4%lowest of 19
Operating margin-438,151.7%10.9%lowest of 19
EV / Sales85,633.6×3.9×most expensive of 19
ROIC minus cost of capital-149.7 pp-0.5 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%85,633.6×n/an/a
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%3.8×31.0%+16.6%
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%216.0×n/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%1.4×-6.4%+12.7%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%3.1×n/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%8.9×36.3%+16.6%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%17.0×n/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%46.5×n/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%3.5×-4.9%+0.2%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a

Questions

Who are Voronoi's main competitors?
Named competitors: Oscotec (039200.KS), HanmiPharm (128940.KS). The cockpit's measured peer set (industry) also includes Marksans Pharma (MARKSANS.NS), Mezzion Pharma (140410.KS), Nippon Shinyaku (4516.T), Damora Therapeutics (DMRA), Phibro Animal Health (PAHC), Xiamen Kingdomway (002626.SZ).
Is Voronoi expensive compared with its peers?
On ev / sales it trades at 85,633.6× against a peer median of 3.9×, most expensive of 19 in its peer set.
How has Voronoi stock performed?
Over six months to 18 Nov 2026 the shares returned -61.9% against -9.1% for the median peer; over one year -49.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.